| HOME >> BIOLOGY >> TECHNOLOGY |
THIRD QUARTER RESULTS OF OPERATIONS
(for the three months ended September 30, 2007 and 2006)
Net loss for the three month period ending September 30, 2007 was $3,763,901 compared to $3,425,169 for the three month period ending September 30, 2006.
Research and Development Expenses ("R&D")
2007 2006
$ $
-------------------------------------------------------------------------
Manufacturing and related process
development expenses 879,937 1,259,716
Clinical trial expenses 1,278,175 688,435
Pre-clinical trial and research
collaboration expenses 293,785 301,165
Other R&D expenses 438,747 456,430
-------------------------------------------------------------------------
Research and development expenses 2,890,644 2,705,746
-------------------------------------------------------------------------
-------------------------------------------------------------------------
For the third quarter of 2007, R&D increased to $2,890,644 compared to $2,705,746 for the third quarter of 2006. The increase in R&D was due to the following:
Manufacturing & Related Process Development ("M&P")
2007 2006
$ $
-------------------------------------------------------------------------
Product manufacturing expenses 610,842 896,776
Technology transfer expenses - 184,761
Process development expenses 269
'/>"/>
| SOURCE Oncolytics Biotech Inc. Copyright©2007 PR Newswire. All rights reserved |